For methotrexate, response relates most closely to which factor?

For methotrexate, response relates most closely to which factor?

• A. Dose
• B. Duration of dosing
• C. Plasma concentration
• D. Frequency of dosing

Answer: (B)

The main idea is that methotrexate’s clinical response is driven by cumulative exposure over time, not just a single high plasma level. After methotrexate is taken, it is taken up by cells and converted to polyglutamated forms, which stay inside cells longer and continue to inhibit folate-dependent processes. This intracellular retention builds up over weeks of therapy, gradually reducing immune cell proliferation and inflammation. Because the therapeutic effect in conditions like rheumatoid arthritis or psoriasis emerges with sustained exposure, the duration of dosing (how long the patient has been on therapy) correlates most strongly with the observed response. A high or peak plasma concentration at a single moment doesn’t guarantee a better outcome if there hasn’t been enough time for intracellular accumulation and the ensuing pharmacodynamic effects to manifest.

The main idea is that methotrexate’s clinical response is driven by cumulative exposure over time, not just a single high plasma level. After methotrexate is taken, it is taken up by cells and converted to polyglutamated forms, which stay inside cells longer and continue to inhibit folate-dependent processes. This intracellular retention builds up over weeks of therapy, gradually reducing immune cell proliferation and inflammation. Because the therapeutic effect in conditions like rheumatoid arthritis or psoriasis emerges with sustained exposure, the duration of dosing (how long the patient has been on therapy) correlates most strongly with the observed response. A high or peak plasma concentration at a single moment doesn’t guarantee a better outcome if there hasn’t been enough time for intracellular accumulation and the ensuing pharmacodynamic effects to manifest.